Thymic stromal lymphopoietin: A potential therapeutic target for allergy and asthma

David P. Huston, Yong Jun Liu

Research output: Contribution to journalReview article

33 Scopus citations

Abstract

Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine that has recently been implicated as central to the microenvironment and is permissive for the immunologic cascade that initiates and propagates allergic immune responses. In humans, TSLP is produced predominantly by epithelial cells and activated mast cells, and stimulates myeloid dendritic cells (mDC), which uniquely express the heterodimeric TSLP receptor. TSLP-activated mDC can promote naïve CD4+ T cells to differentiate into a Th2 phenotype and can promote the expansion of CD4+ Th2 memory cells. Recent evidence implicates TSLP as playing a pivotal role in the pathobiology of allergic asthma and atopic dermatitis. The potential for TSLP to provide a new therapeutic target for the treatment of allergic disorders is compelling, and elucidating the mechanisms that regulate TSLP expression and the effects of TSLP on orchestrating the immune response toward a Th2 phenotype should facilitate this quest.

Original languageEnglish (US)
Pages (from-to)372-376
Number of pages5
JournalCurrent Allergy and Asthma Reports
Volume6
Issue number5
DOIs
StatePublished - Sep 1 2006

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Thymic stromal lymphopoietin: A potential therapeutic target for allergy and asthma'. Together they form a unique fingerprint.

Cite this